secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001140361-25-011767
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY
------------------------------------------------------------------------

- Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.
- GAAP net loss $4.4M ($0.11 loss per share); adjusted loss $0.08 per share; adjusted EBITDA $1.3M vs -$3.6M a year ago.
- FY2025 guidance raised: net sales $285-288M, Med Tech growth 14-16%, gross margin 53-54%, adjusted EBITDA $4-5M, adjusted EPS loss $(0.31)-(0.34).
- Received FDA 510(k) clearance for NanoKnife System for prostate tissue ablation; initiated AMBITION BTK RCT for Auryon.
- Secured $25M revolver commitment from J.P. Morgan for working capital flexibility; expects positive operating cash flow in Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036125011767/0001140361-25-011767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036125011767/ef20046769_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-011767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer